Research programme: kinase inhibitors - ocular diseases - MethylGene/Otsuka

Drug Profile

Research programme: kinase inhibitors - ocular diseases - MethylGene/Otsuka

Latest Information Update: 15 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MethylGene
  • Class Small molecules
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Eye disorders

Most Recent Events

  • 30 Jun 2010 Methylgene and Otsuka extend their agreement for the development of small molecule kinase inhibitors in ocular diseases
  • 27 Mar 2008 Preclinical trials in Eye disorders in Canada (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top